Lumiliximab is a monoclonal antibody that targets CD23. It acts as an immunomodulator  and, as of October 2009, it is being investigated in Phase I and II clinical ...
Lumiliximab: The Next Drug in CLL? Date: March 6, 2007. by Chaya Venkat. A New ‘Babe’ in Town. Related Article: IDEC 152. Anytime there is a new monoclonal ...
1. J Allergy Clin Immunol. 2005 Oct;116(4):780-8. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T ...
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
lumiliximab (uncountable) Wikipedia has an article on: lumiliximab. Wikipedia. A chimeric monoclonal antibody being investigated for the treatment of chronic ...
CD23 plays a role in the regulation of IgE production and allergy-induced immune and inflammatory responses. A novel anti-CD23 monoclonal antibody, lumiliximab,
This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to ...
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) (LUCID)
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials.